Form 13-F position report

IMMUNITYBIO INC COM (DE)

Reported by Swiss National Bank

IBRX CUSIP 45256X103 Manager CIK 0001582202

Reported 284,600 shares, up 25,400 (9.8%) from the prior quarter.

Reported value 67.7%; share count 9.8% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2023
Shares 284,600 Quarter-end amount reported
Reported value $791,188 Fair value at quarter end
Consecutive quarters held 10 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 1652000
2021-12-31 1046000
2022-03-31 1055000
2022-06-30 1046000
2022-09-30 1397000
2022-12-31 1470300
2023-03-31 471744
2023-06-30 791188
2023-09-30 480974
2023-12-31 1320762
2024-03-31 1412847
2024-06-30 1662792
2024-09-30 1004400
2024-12-31 701440
2025-03-31 1235304
2025-06-30 1112760
2025-09-30 1263210
2025-12-31 1291752
2026-03-31 5234008
2026-06-30 6321110

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for IMMUNITYBIO INC COM (DE) held by Swiss National Bank.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Added 722,000 +39,600 (5.8%) < 0.01% $6,321,110 2026-08-11
Q1 2026 Added 682,400 +30,000 (4.6%) < 0.01% $5,234,008 2026-05-07
Q4 2025 Added 652,400 +138,900 (27.0%) < 0.01% $1,291,752 2026-02-12
Q3 2025 Added 513,500 +92,000 (21.8%) < 0.01% $1,263,210 2025-11-13
Q2 2025 Added 421,500 +11,100 (2.7%) < 0.01% $1,112,760 2025-08-12
Q1 2025 Added 410,400 +136,400 (49.8%) < 0.01% $1,235,304 2025-05-12
Q4 2024 Added 274,000 +4,000 (1.5%) < 0.01% $701,440 2025-02-10
Q3 2024 Added 270,000 +6,900 (2.6%) < 0.01% $1,004,400 2024-11-07
Q2 2024 Unchanged 263,100 0 (0.0%) < 0.01% $1,662,792 2024-08-08
Q1 2024 Unchanged 263,100 0 (0.0%) < 0.01% $1,412,847 2024-05-07
Q4 2023 Reduced 263,100 -21,500 (-7.6%) < 0.01% $1,320,762 2024-02-06
Q3 2023 Unchanged 284,600 0 (0.0%) < 0.01% $480,974 2023-11-08
Q2 2023 Added 284,600 +25,400 (9.8%) < 0.01% $791,188 2023-08-09
Q1 2023 Reduced 259,200 -30,800 (-10.6%) < 0.01% $471,744 2023-05-10
Q4 2022 Added 290,000 +8,900 (3.2%) < 0.01% $1,470,300 2023-02-08
Q3 2022 Unchanged 281,100 0 (0.0%) < 0.01% $1,397,000 2022-11-09
Q2 2022 Added 281,100 +93,100 (49.5%) < 0.01% $1,046,000 2022-08-09
Q1 2022 Added 188,000 +15,900 (9.2%) < 0.01% $1,055,000 2022-05-09
Q4 2021 Added 172,100 +2,500 (1.5%) < 0.01% $1,046,000 2022-02-08
Q3 2021 Added 169,600 +85,500 (101.7%) < 0.01% $1,652,000 2021-11-08
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

161 managers reported IMMUNITYBIO INC COM (DE) for Q2 2023.

Managers reporting IMMUNITYBIO INC COM (DE) in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 10,333,301 +2,047,343 < 0.01% $28,726,578 10 qtrs
BlackRock Inc Added 9,498,666 +2,533,147 < 0.01% $26,406,292 10 qtrs
STATE STREET CORPORATION Added 2,777,236 +127,423 < 0.01% $7,720,716 10 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 2,730,452 +784,588 < 0.01% $7,590,656 10 qtrs
JPMorgan Chase & Co Reduced 1,478,953 -134,344 < 0.01% $4,111,489 10 qtrs
NORTHERN TRUST CORPORATION Added 1,161,699 +350,006 < 0.01% $3,229,523 10 qtrs
CREDIT SUISSE AG Added 1,016,494 +126,795 < 0.01% $2,825,854 10 qtrs
CHARLES SCHWAB INVESTMENT MANAGEMENT INC Added 978,547 +262,912 < 0.01% $2,720,361 10 qtrs
NATIONAL BANK OF CANADA FI Added 795,400 +663,300 < 0.01% $2,179,396 7 qtrs
ALLEN HOLDING INC NY Unchanged 687,571 0 0.26% $1,911,447 9 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 09, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
284,600
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.